Eribulin Mesylate Patent Expiration

Eribulin Mesylate is Used for treating patients with metastatic breast cancer. It was first introduced by Eisai Inc in its drug Halaven on Nov 15, 2010. 3 different companies have introduced drugs containing Eribulin Mesylate.


Eribulin Mesylate Patents

Given below is the list of patents protecting Eribulin Mesylate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Halaven US6214865 Macrocyclic analogs and methods of their use and preparation Jun 16, 2019

(Expired)

Eisai Inc
Halaven US6214865

(Pediatric)

Macrocyclic analogs and methods of their use and preparation Jan 20, 2024

(Expired)

Eisai Inc
Halaven US6469182 Intermediates in the preparation of macrocyclic analogs Jun 16, 2019

(Expired)

Eisai Inc
Halaven US7470720 Methods and compositions for use in treating cancer Jun 16, 2019

(Expired)

Eisai Inc
Halaven US8097648 Methods and compositions for use in treating cancer Jan 22, 2021

(Expired)

Eisai Inc
Halaven USRE46965 Intermediates for the preparation of analogs of Halichondrin B Jan 08, 2027 Eisai Inc
Halaven USRE46965

(Pediatric)

Intermediates for the preparation of analogs of Halichondrin B Jul 08, 2027 Eisai Inc


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳

Eribulin Mesylate Generics

Several generic applications have been filed for Eribulin Mesylate. The first generic version for Eribulin Mesylate was by Gland Pharma Ltd and was approved on Apr 5, 2024. And the latest generic version is by Jiangxi Qingfeng Pharmaceutical Co Ltd and was approved on Jun 28, 2024.

Given below is the list of companies who have filed for Eribulin Mesylate generic.


1. GLAND PHARMA LTD

Gland Pharma Ltd has filed for 1 generic for Eribulin Mesylate. Given below are the details of the strengths of this generic introduced by Gland Pharma Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
1MG/2ML (0.5MG/ML) solution Prescription INTRAVENOUS AP Apr 5, 2024


2. JIANGXI QINGFENG

Jiangxi Qingfeng Pharmaceutical Co Ltd has filed for 1 generic for Eribulin Mesylate. Given below are the details of the strengths of this generic introduced by Jiangxi Qingfeng.

Strength Dosage Form Availability Application Pathway TE code Launch Date
1MG/2ML (0.5MG/ML) solution Prescription INTRAVENOUS AP Jun 28, 2024